Bacille Calmette-Guérin (BCG) Vaccine

Bacille Calmette-Guérin (BCG) Vaccine

Context

On April 14, 2026, India delivered 13 tonnes of Bacille Calmette-Guérin (BCG) vaccines and associated dry supplies to Afghanistan’s Ministry of Public Health. This humanitarian consignment is aimed at augmenting Afghanistan's national child immunization programme and protecting vulnerable infants from tuberculosis (TB).

About the BCG Vaccine

• What it is: A live attenuated (weakened) vaccine primarily used to protect against TB. It remains the only licensed vaccine for TB and is part of the World Health Organization’s (WHO) Expanded Programme on Immunization (EPI).
• Developed By: French scientists Albert Calmette and Camille Guérin at the Pasteur Institute. It was first administered to humans in 1921 after 13 years of rigorous research.
• Components:
  • Active Ingredient: A weakened strain of Mycobacterium bovis (bovine TB), which is closely related to the bacteria that causes human TB.
  • Excipients: Stabilizers such as glycerol, citric acid, and magnesium salts to preserve potency.
  • Form: Usually supplied in a freeze-dried (lyophilized) state, requiring reconstitution with a diluent before injection.

How It Works

The vaccine utilizes a "prime and protect" mechanism:

1. Immune Priming: By introducing a weakened bacterium, the body’s immune system learns to recognize mycobacterial proteins without contracting the disease.
2. Cellular Response: It specifically stimulates T-cell production, which is vital for fighting intracellular pathogens like TB.
3. Memory: Should the person be exposed to Mycobacterium tuberculosis later in life, their immune system can mount a rapid, localized defense to prevent the infection from spreading to critical organs.

Key Features & Administration

• Administration: Given via intradermal injection (just under the top layer of skin), typically in the upper left arm.
• The BCG Scar: A distinct characteristic where a small papule forms, occasionally ulcers, and eventually heals into a permanent, flat scar.
• Target Group: Most effective when given to newborns and infants in countries with high TB prevalence.
• Alternative Uses: It is used as a highly effective immunotherapy for treating non-muscle invasive bladder cancer.

Significance

• Childhood Survival: It provides 70–80% protection against the most severe forms of childhood TB, including TB meningitis and miliary (disseminated) TB.
• Cross-Protection: It offers partial protection against other mycobacterial infections, such as Leprosy and Buruli ulcer.
• Vaccine Diplomacy: For India, providing 13 tonnes of medical supplies to Afghanistan reinforces its role as the "Pharmacy of the World" and a committed humanitarian partner in South Asia.

Conclusion

While the BCG vaccine’s efficacy against adult pulmonary TB varies across different geographies, its role in preventing lethal childhood TB is undisputed. India's recent shipment to Afghanistan underscores the global importance of the vaccine not just as a medical tool, but as a bridge for international solidarity and public health resilience.